Despite this setback, further research is warranted, since (1) Nrf2 activation still is one of the most promising therapeutic approaches in CKD and (2) there exists a variety of other substance classes with Nrf2-activating potential, which might not have similar severe side effects as bardoxolone methyl. This evidence concerns the gene NFE2L2 and chronic kidney disease.